Share on StockTwits

Alexza Pharmaceuticals (NASDAQ:ALXA) was downgraded by Roth Capital from a “buy” rating to a “neutral” rating in a research note issued on Friday, reports. They currently have a $5.50 target price on the stock, down from their previous target price of $10.00. Roth Capital’s price target suggests a potential upside of 36.14% from the company’s current price.

Shares of Alexza Pharmaceuticals (NASDAQ:ALXA) traded down 16.87% during mid-day trading on Friday, hitting $4.04. 938,667 shares of the company’s stock traded hands. Alexza Pharmaceuticals has a 52-week low of $3.63 and a 52-week high of $5.93. The stock has a 50-day moving average of $4.69 and a 200-day moving average of $4.6. The company’s market cap is $70.0 million.

Alexza Pharmaceuticals (NASDAQ:ALXA) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.33. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $2.24 million. On average, analysts predict that Alexza Pharmaceuticals will post $-2.35 earnings per share for the current fiscal year.

Alexza Pharmaceuticals, Inc (NASDAQ:ALXA) is a pharmaceutical company focused on the research, development, and commercialization of products for the acute treatment of central nervous system (CNS) conditions.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.